Immunovent LLC

Summit Biomedical Imaging, LLC is a pioneering company based in New York, NY, specializing in the development of fluorescent biomarkers for the early and accurate detection of various cancers. Their proprietary technology, PARPi-FL, specifically targets oral cancer by detecting overexpression of PARP, a DNA repair enzyme commonly found in many cancers. With a mission to become the world leader in fluorescence-based diagnostics and surgical support, Summit Biomedical Imaging is dedicated to improving patient outcomes by developing innovative fluorescent biomarkers that effectively identify and aid in the removal of cancerous cells. Their research focuses on targeting PARP, an enzyme that is overexpressed in numerous cancers, including lung, colorectal, and cervical cancer.Generated from the website

Volastra Therapeutics, Inc. is a biotechnology company based in New York, NY, specializing in the development of innovative therapies for patients. With a dedicated team of experts and a strong focus on scientific research, Volastra Therapeutics aims to make significant contributions to the field of medicine. Through their commitment to advancing science and their extensive pipeline of potential treatments, Volastra Therapeutics is dedicated to improving the lives of patients and addressing unmet medical needs. With a strong emphasis on collaboration and partnerships, the company strives to bring their groundbreaking discoveries to the forefront of medical innovation.Generated from the website

Project A.L.S.' is the new paradigm for brain disease research. The mission is to recruit the world's finest scientists and clinicians to work together-rationally and aggressivelytoward an understanding of and the first effective treatments for ALS ( amyotrophic lateral sclerosis ), also known as Lou Gehrig's disease. Project A.L.S.' was founded in 1998, as a non-profit 501C3, by Jenifer Estess, her family, and friends, when Jenifer was diagnosed with the fatal brain disease at the age of thirty-five. To date, Project A.L.S.' has raised $52 million, directing over 82% to research programs.